Crispr Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Hold” by Brokerages

Crispr Therapeutics AG (NASDAQ:CRSP) has been given an average recommendation of “Hold” by the fifteen analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $49.88.

Several research firms have issued reports on CRSP. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target (down previously from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Evercore ISI began coverage on Homology Medicines in a research note on Thursday, April 11th. They issued an “outperform” rating and a $29.00 price target on the stock. BTIG Research lifted their price target on Crispr Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, April 22nd. Zacks Investment Research downgraded EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, Chardan Capital set a $73.00 price target on Crispr Therapeutics and gave the company a “buy” rating in a research note on Friday, June 7th.

In other news, President Rodger Novak sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $50.00, for a total value of $2,500,000.00. Following the completion of the transaction, the president now owns 848,007 shares in the company, valued at approximately $42,400,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $42.03, for a total value of $840,600.00. Following the completion of the transaction, the chief executive officer now owns 186,542 shares of the company’s stock, valued at approximately $7,840,360.26. The disclosure for this sale can be found here. Insiders sold a total of 160,000 shares of company stock valued at $7,511,000 in the last 90 days. 21.40% of the stock is owned by corporate insiders.



Several hedge funds and other institutional investors have recently made changes to their positions in the company. LPL Financial LLC boosted its stake in Crispr Therapeutics by 24.4% in the 4th quarter. LPL Financial LLC now owns 9,809 shares of the company’s stock worth $280,000 after buying an additional 1,924 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Crispr Therapeutics by 277.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 21,586 shares of the company’s stock worth $616,000 after buying an additional 15,868 shares during the last quarter. California Public Employees Retirement System boosted its stake in Crispr Therapeutics by 197.6% in the 4th quarter. California Public Employees Retirement System now owns 72,557 shares of the company’s stock worth $2,073,000 after buying an additional 48,174 shares during the last quarter. Raymond James & Associates boosted its stake in Crispr Therapeutics by 12.1% in the 4th quarter. Raymond James & Associates now owns 48,557 shares of the company’s stock worth $1,387,000 after buying an additional 5,227 shares during the last quarter. Finally, Resources Investment Advisors Inc. acquired a new stake in Crispr Therapeutics in the 4th quarter worth about $43,000. Institutional investors own 48.96% of the company’s stock.

Shares of CRSP traded down $0.07 during midday trading on Monday, hitting $49.11. The stock had a trading volume of 287,431 shares, compared to its average volume of 566,607. The firm has a 50 day moving average of $43.23. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $66.26. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of -14.28 and a beta of 3.11. The company has a current ratio of 15.84, a quick ratio of 15.84 and a debt-to-equity ratio of 0.08.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, April 29th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.03). Crispr Therapeutics had a negative net margin of 8,839.02% and a negative return on equity of 50.90%. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $1.50 million. During the same period in the prior year, the business earned ($0.62) EPS. The business’s revenue for the quarter was down 78.6% compared to the same quarter last year. On average, sell-side analysts predict that Crispr Therapeutics will post -3.82 earnings per share for the current fiscal year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Book Value Per Share – BVPS

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.